Overview

Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.

Phase:

Phase 2

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Collaborators:

Asan Medical Center
Samsung Medical Center
Seoul National University Hospital
Ulsan University Hospital

Treatments:

Belotecan
Camptothecin